Synonyms: compound 139 [WO2019160882A1] | GS-4224 | GS4224 | PD-1/PD-L1-IN 7
Compound class:
Synthetic organic
Comment: We obtained the chemical structure for evixapodlin from WHO Proposed list 125 of July 2021. The INN record describes it as a programmed cell death ligand 1 (PD-L1) inhibitor. Evixapodlin is one of the chemical structures that is claimed in Gilead Sciences' patent WO2019160882A1 (compound number 139) [1]. It was developed as an alternative to monocloncal antibody PD-L1/PD-1 interaction inhibitors, for potential anticancer and antiviral activities. First disclosures at the ACS meeting in Chicago in 2022 mapped evixapodlin to Gilead's clinical lead GS-4224. GS-4224 is orally bioavailable.
|
|
Bioactivity Comments |
Evixapodlin inhibits the interaction of PD-L1 with its receptor PD-1 (IC50 0.2 nM) [1]. |